Áö¼ÓÀûÀÎ ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ® Á¦Á¦ »ç¿ëÀ¸·Î ¹ß»ýÇÑ ´ëÅðºÎ ºÎÀü °ñÀýÀÇ Ä¡·á ¹× °æ°ú
Treatment and Prognosis of Femoral Insufficiency Fracture Associated with Prolonged Bisphosphonate Use

´ëÇѰñÀýÇÐȸÁö 2014³â 27±Ç 1È£ p.10 ~ p.16

¾È±âÂù(An Ki-Chan) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ºÎ»ê¹éº´¿ø Á¤Çü¿Ü°úÇб³½Ç
¹Ú´ëÇö(Park Dae-Hyun) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ºÎ»ê¹éº´¿ø Á¤Çü¿Ü°úÇб³½Ç
°ø±Ô¹Î(Kong Gyu-Min) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ºÎ»ê¹éº´¿ø Á¤Çü¿Ü°úÇб³½Ç
±èÁÖ¿ë(Kim Joo-Yong) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ºÎ»ê¹éº´¿ø Á¤Çü¿Ü°úÇб³½Ç
±è»ó¹ü(Kim Sang-Bum) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ºÎ»ê¹éº´¿ø Á¤Çü¿Ü°úÇб³½Ç
»ç°ø½Â¿±(Sakong Seung-Yeob) - ÀÎÁ¦´ëÇб³ Àǰú´ëÇÐ ºÎ»ê¹éº´¿ø Á¤Çü¿Ü°úÇб³½Ç

Abstract

¸ñÀû: Áö¼ÓÀûÀÎ ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ® Á¦Á¦ »ç¿ë ÈÄ ¹ß»ýÇÑ ´ëÅðºÎ ºÎÀü °ñÀý ȯÀÚ ºÐ¼®À» ÅëÇØ °ñÀý¿¡ ´ëÇÑ ÀûÀýÇÑ Ä¡·á¹ýÀ» ¾Ë¾Æº¸°íÀÚ ÇÑ´Ù.

´ë»ó ¹× ¹æ¹ý: 5³â ÀÌ»ó ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ® Á¦Á¦¸¦ º¹¿ëÇÑ °ú°Å·ÂÀ» °¡Áø ȯÀÚ Áß ´ëÅð°ñ ÀüÀÚÇÏ ¹× ´ëÅð°ñ °£ºÎ¿¡ Ư¡ÀûÀÎ ¹æ»ç¼±Àû ¼Ò°ßÀ» º¸ÀÌ´Â °ñÀý ȤÀº ÀÓ¹Ú °ñÀýÀÌ ÀÖ´Â 10¸íÀÇ 13 Áõ·Ê¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. Àü±¸ Áõ»ó ¹× ¾çÃø¼º, ¼ú ÈÄ ÅëÁõ ¼Ò½Ç ±â°£ ¹× µ¶¸³ º¸Çà °¡´É ½ÃÁ¡, ¼ú ÈÄ ÇÕº´Áõ¿¡ ´ëÇØ Á¶»çÇÏ¿´´Ù.

°á°ú: 13¿¹ Áß 7¿¹¿¡¼­ Àü±¸ Áõ»óÀ¸·Î ¼­ÇýºÎ ¹× °ñ¹Ý ÅëÁõÀ» È£¼ÒÇÏ¿´°í(53.8%) 3¸í¿¡¼­´Â ¾çÃø¼º °ñÀý·Î ³ªÅ¸³µ´Ù(30%). ÃÑ 6¿¹¿¡ ÀÖ¾î Àü±¸Áõ»óÀÌ ÀÖ´Â ÀÓ¹Ú °ñÀýÀÌ °üÂûµÇ¾úÀ¸¸ç(46.2%) 3¿¹¿¡ ´ëÇØ °ñ¼ö°­ ³» ±Ý¼ÓÁ¤À» ÀÌ¿ëÇÑ ¿¹¹æÀû °íÁ¤¼úÀ» ½ÃÇàÇÏ¿´°í ÀÓ¹Ú °ñÀýÀÌ ÀÖ´ø 3¿¹ Áß 2¿¹¿¡¼­ Æò±Õ 11°³¿ù(3-19°³¿ù)¸¸¿¡ ¿ÏÀü °ñÀýÀÌ ¹ß»ýÇÏ¿´´Ù. ¿¹¹æÀû °íÁ¤¼úÀ» ½ÃÇàÇß´ø 3¿¹¿¡´Â ¼ú ÈÄ ÇÕº´ÁõÀÌ ¹ß»ýÇÏÁö ¾Ê¾Ò°í ¼ú ÈÄ 1³â À̳» ¸ðµÎ ¹æ»ç¼±Àû À¯ÇÕ ¼Ò°ßÀ» °üÂûÇÒ ¼ö ÀÖ¾ú´Ù. °ñÀý ÈÄ ¼ö¼úÀ» ½ÃÇàÇß´ø 9¿¹¿¡¼­´Â ºÒÀ¯ÇÕÀÌ 2¿¹ ÀÖ¾úÀ¸¸ç ¼ö¼ú ºÎÀ§ ÅëÁõ ¼Ò½ÇÀº ¼ú ÈÄ Æò±Õ 4.7°³¿ù(3-9°³¿ù)À̾ú°í µ¶¸³ º¸ÇàÀº ¼ú ÈÄ Æò±Õ 5.2°³¿ù(3-9°³¿ù)·Î Á¶»çµÇ¾ú´Ù.

°á·Ð: Àå±â°£ÀÇ ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ® Á¦Á¦ º¹¿ë ȯÀÚ¿¡¼­ Àü±¸ Áõ»óÀº ´ëÅð°ñ ÀüÀÚÇÏ °ñÀý ¹× °£ºÎ °ñÀý ¹ß»ýÀÇ À¯¿ëÇÑ ÁöÇ¥°¡ µÉ ¼ö ÀÖ´Ù. ÀÓ¹Ú °ñÀýÀÇ °æ¿ì ¿ÏÀü °ñÀý ¹ß»ý °¡´É¼ºÀÌ ¸Å¿ì ³ôÀ¸¸ç ÀÌ¿¡ ´ëÇÑ ¿¹¹æÀû °íÁ¤¼ú ½ÃÇàÀº ¿ì¼öÇÑ ÀÓ»ó °æ°ú¸¦ º¸ÀδÙ.
Purpose: This study was conducted to investigate and identify an appropriate fracture treatment method by analyzing patients in whom a femoral incompetence fracture occurred after receiving a long-term bisphosphonate administration.

Materials and Methods: The subjects of this study were 13 cases out of ten patients among those who had a history of receiving bisphosphonate for more than five years and had a fracture or an imminent fracture with a characteristic radiological finding in the femoral subtrochanteric region and the interfemoral region. The period of the drug administration, bone density, the existence of a prodromal symptom, and bilateral fracture were investigated.

Results: In seven out of the 13 cases, the patients complained of painat the femoral and pelvic parts as a prodrome (53.8%), and three of them showed a bilateral fracture (30%). An imminent fracture with a prodrome was observed in six cases (46.2%); for three of these cases, a prophylactic fixture pexis was performed by inserting a metal nail into the medullary cavity, and in two out of these three, a complete fracture was found within 11 months on average (3 to 19 months). In the three prophylactic fixture pexis performed cases, no postoperative complications were found, and a radiological finding of concrescence was seen within one year after the operation. Among the nine operation performed cases after the fracture, non-union was found in two.

Conclusion: In the patients who have received bisphosphonate for a long periodof time, a prodome may be a useful indicator of a fracture in the femoral subtrochanteric region and the interfemoral region; therefore, a careful observation is necessary. A prophylactic internal fixation is recommended for patients with imminent fracture with a prodome since they have a high risk of a complete fracture is high in them.

Ű¿öµå

ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®, ´ëÅð°ñ ºÎÀü °ñÀý, ´ëÅð°ñ ÀÓ¹Ú °ñÀý
Bisphophonate, Femoral incompetence fracture, Femoral imminent fracture
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå